喜炎平与阿糖腺苷治疗小儿病毒性脑炎的疗效及对其T细胞亚群的影响  

Efficacy of xiyanping and vidarabine on children with viral encephalitis and its influence on T cell subsets

作　　者：杨小利[1] 殷亚楠[2] 胡文淼[1] 朱红文[1] 张理斐[1] 童丽[1] 

机构地区：[1]郑州市第三人民医院儿科,450000 [2]郑州市第二人民医院神经内科,450000

出　　处：《中国实用医刊》2017年第12期88-90,共3页Chinese Journal of Practical Medicine

摘　　要：目的 探讨喜炎平与阿糖腺苷治疗小儿病毒性脑炎的疗效及对T细胞亚群的影响.方法 选取2015年4月至2016年3月小儿病毒性脑炎患者98例,根据治疗方案分两组,每组49例.对照组给予阿糖腺苷,研究组给予阿糖腺苷及喜炎平,两组均持续治疗7 d.比较两组临床疗效及治疗前后T细胞亚群（CD3＋、CD4＋、CD8＋）水平.结果 研究组总有效率93.88%（46/49）高于对照组79.60%（39/49）,差异有统计学意义（P＜0.05）;研究组呕吐消失、抽搐消失、头痛消失、发热消失及意识恢复正常时间少于对照组,差异有统计学意义（P＜0.05）;治疗后,研究组CD3＋（62.4±7.2）个/μl、CD4＋（51.3±8.1）个/μl、CD8＋（32.3±7.3）个/μl, 优于对照组,差异有统计学意义（P＜0.05）;研究组后遗症发生率14.28%（7/49）低于对照组32.65%（16/49）,差异有统计学意义（P＜0.05）;研究组不良反应发生率6.12%（3/49）与对照组4.08%（2/49）比较,差异未见统计学意义（P＞0.05）.结论 喜炎平与阿糖腺苷治疗小儿病毒性脑炎疗效确切,可有效缓解患儿临床症状,改善T细胞亚群水平,减少后遗症,有一定安全性.Objective To investigate the efficacy of xiyanping combined with vidarabine on children with viral encephalitis and its influence on T cell subsets.Methods A total of 98 children with viral encephalitis were selected from April 2015 to March 2016, and were divided into the two groups according to treatment options, with 49 cases in each group. The control group was treated by adenosine, the study group was given adenosine and Xiyanping. Two groups were treated with continuous 7 d. The effect and T cell subsets （CD3＋、CD4＋、CD8＋） levels were compared between the two groups.Results The total effective rate of the study group was 93.88%（46/49）,which of the of the control group was 79.60%（39/49）, the difference was significant （P〈0.05）. The disappearance time, the disappearance time of headache, the disappearance time of fever and the recovery of consciousness of the study group were less than those of the control group, and the differences were significant （P〈0.05）. After the treatment, CD3＋（62.4±7.2）/μl,CD4＋（51.3±8.1）/μl,CD8＋（32.3±7.3）/μl of the study group were better than those of the control group, the differences were significant （P〈0.05）. The incidence rate in the study group was 14.28%（7/49）, which of the of the control group was 32.65%（16/49）, the difference was significant （P〈0.05）. The incidence rate of adverse reaction in the study group was 6.12%（3/49）, which of the of the control group was 4.08%（2/49）, the difference was not significant （P〉0.05）.Conclusions The effect of Xiyanping combined with vidarabine on children virus encephalitis is exact, and it can effectively relieve the clinical symptoms, and can improve the level of T cell subsets reduce sequelae, and it is safe.

关 键 词：小儿病毒性脑炎 T细胞亚群 喜炎平 阿糖腺苷 

分 类 号：R725.1[医药卫生—儿科]